57 related articles for article (PubMed ID: 29616847)
41. Management of patients with acute promyelocytic leukemia.
Kayser S; Schlenk RF; Platzbecker U
Leukemia; 2018 Jun; 32(6):1277-1294. PubMed ID: 29743722
[TBL] [Abstract][Full Text] [Related]
42. Retinoic acid and arsenic for treating acute promyelocytic leukemia.
Zhou GB; Zhao WL; Wang ZY; Chen SJ; Chen Z
PLoS Med; 2005 Jan; 2(1):e12. PubMed ID: 15696202
[TBL] [Abstract][Full Text] [Related]
43. All-trans retinoic acid-induced focal myositis, synovitis, and mononeuritis.
Yu W; Burns CM
J Clin Rheumatol; 2009 Oct; 15(7):358-60. PubMed ID: 20009973
[TBL] [Abstract][Full Text] [Related]
44. Differentiation syndrome in patients with acute promyelocytic leukemia.
Rogers JE; Yang D
J Oncol Pharm Pract; 2012 Mar; 18(1):109-14. PubMed ID: 21364078
[TBL] [Abstract][Full Text] [Related]
45. Management of acute promyelocytic leukemia.
Fenaux P
Eur J Haematol; 1993 Feb; 50(2):65-73. PubMed ID: 8382622
[No Abstract] [Full Text] [Related]
46. The impact of all-trans-retinoic acid on the coagulopathy of acute promyelocytic leukemia.
Barbui T; Finazzi G; Falanga A
Blood; 1998 May; 91(9):3093-102. PubMed ID: 9558362
[No Abstract] [Full Text] [Related]
47. A candidate for lung cancer treatment: arsenic trioxide.
Huang W; Zeng YC
Clin Transl Oncol; 2019 Sep; 21(9):1115-1126. PubMed ID: 30756240
[TBL] [Abstract][Full Text] [Related]
48. Biology and treatment of acute promyelocytic leukemia.
Fenaux P; Chomienne C
Curr Opin Oncol; 1996 Jan; 8(1):3-12. PubMed ID: 8868093
[TBL] [Abstract][Full Text] [Related]
49. Reassessing the hemostatic disorder associated with acute promyelocytic leukemia.
Tallman MS; Kwaan HC
Blood; 1992 Feb; 79(3):543-53. PubMed ID: 1732003
[No Abstract] [Full Text] [Related]
50. Current status and future prospects of nanomedicine for arsenic trioxide delivery to solid tumors.
Sönksen M; Kerl K; Bunzen H
Med Res Rev; 2022 Jan; 42(1):374-398. PubMed ID: 34309879
[TBL] [Abstract][Full Text] [Related]
51. Extramedullary disease and targeted therapies for hematological malignancies--is the association real?
Raanani P; Shpilberg O; Ben-Bassat I
Ann Oncol; 2007 Jan; 18(1):7-12. PubMed ID: 16790518
[TBL] [Abstract][Full Text] [Related]
52. Arsenic trioxide in the treatment of platinum-resistant recurrent endometrial cancer: a case report and literature review.
Cai H; Li X; Wang J
J Obstet Gynaecol; 2020 Jan; 40(1):137-138. PubMed ID: 31210078
[No Abstract] [Full Text] [Related]
53. Switching from all-trans retinoic acid to arsenic trioxide for newly diagnosed acute promyelocytic leukemia.
Imagawa J
Leuk Lymphoma; 2018 Dec; 59(12):3013-3015. PubMed ID: 29616847
[No Abstract] [Full Text] [Related]
54. [Acute promyelocytic leukaemia].
Tøstesen M; Østergård LSG; Kjeldsen E; Stentoft J; Nørgaard JM
Ugeskr Laeger; 2018 Jan; 180(3):. PubMed ID: 29336301
[TBL] [Abstract][Full Text] [Related]
55. [Acute Promyelocytic Leukemia: New treatment strategies with ATRA and ATO - AML-BFM-Recommendations].
Creutzig U; Dworzak M; von Neuhoff N; Rasche M; Reinhardt D
Klin Padiatr; 2018 Oct; 230(6):299-304. PubMed ID: 30399642
[TBL] [Abstract][Full Text] [Related]
56. Acute Promyelocytic Leukemia.
Winkler C
N Engl J Med; 2024 May; 390(17):e42. PubMed ID: 38683728
[No Abstract] [Full Text] [Related]
57. [Coagulopathy and differentiation syndrome: the main complications of the initial treatment of acute promyelocytic leukemia].
Korístek Z; Zák P
Vnitr Lek; 2008; 54(7-8):745-50. PubMed ID: 18780573
[TBL] [Abstract][Full Text] [Related]
[Previous] [New Search]
